ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Texas A&M Health and BurstIQ, a leader in advanced data management, today announced a partnership to leverage LifeGraph®, a graph-powered, end-to-end data management platform, to transform clinical research. This collaboration aims to enhance patient and researcher interactions while ensuring the highest standards of patient privacy and data rights.
The US Food and Drug Administration (FDA) has granted a priority review for Roche’s inavolisib as a combination therapy with fulvestrant and Pfizer’s Ibrance (palbociclib) as a treatment for breast cancer.
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy.
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Roche`s inavolisib combo cuts breast cancer progression by 57%
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be...
Astex Pharmaceuticals, a pharmaceutical company developing small molecule therapeutics for oncology and diseases of the central nervous system, has earned a milestone payment from AstraZeneca for the first commercial sale of Truqap plus Faslodex for HR-positive, HER2-negative locally advanced or metastatic breast cancer in the U.S. following the U.S. FDA’s approval.
TRUQAP™ (capivasertib) plus fulvestrant approved in the US
US FDA approves AstraZeneca`s breast cancer drug combination
The FDA and Eagle Pharmaceuticals have agreed on the next steps for the development of EA-114, an estrogen receptor antagonist and novel formulation of fulvestrant (Faslodex) used in the treatment of postmenopausal women with breast cancer. The consensus was reached in a Type C meeting with the regulatory agency and company representatives.